SKU:K1313 | M. Wt:256.25 | ||
Formula:C15H12O4 | Solubility:N/A | ||
Purity:>99% | Storage:2 years at -20 degrees centigrade | ||
CAS No.:961-29-5 | Synonyms:N/A | ||
Chemical NameN/A |
供货周期: | 一周 |
品牌: | |
规格: | 2mg |
货号: | K1313 |
CAS号: | 961-29-5 |
SKU:K1313 | M. Wt:256.25 | ||
Formula:C15H12O4 | Solubility:N/A | ||
Purity:>99% | Storage:2 years at -20 degrees centigrade | ||
CAS No.:961-29-5 | Synonyms:N/A | ||
Chemical NameN/A |
Description | Isoliquiritigenin (ISL) is a chalcone compound with valuable pharmacological properties such as antioxidant, anti-inflammatory, anticancer and anti-allergic activities.Isoliquiritigenin, a chalcone compound, is a positive allosteric modulator of GABA receptors and shows hypnotic effects. | |||||
---|---|---|---|---|---|---|
Targets | ||||||
IC50 | N/A | |||||
In vitro | Isoliquiritigenin (ISL) is a chalcone compound with valuable pharmacological properties such as antioxidant, anti-inflammatory, anticancer and anti-allergic activities.Isoliquiritigenin, a chalcone compound, is a positive allosteric modulator of GABA A receptors and shows hypnotic effects. ISL also can suppress HIF-1alpha level, VEGF expression and secretion, cell migration and to decrease the expression and secretion of MMP-9/-2. ISL inhibited the proliferation of U87 cells in a time-dependent and dose-dependent manner.ISL induced the apoptosis of the U87 cells and blocked cell cycle progression at the S and G2/M phases. ISL induced the apoptosis of the U87 cells in a caspase-dependent manner. ISL upregulated p21/WAF1 and p27. Cell cycle arrest and the caspase-mediated apoptosis pathway may participate in the antiproliferative activity of ISL in U87 cells by regulating the expression of ISL. There is a strong dose-response relationship between ISL exposure and the characteristics of B16F0 differentiation in terms of morphology changes and melanogenesis. Isoliquiritigenin also can inhibit one of the most drug-metabolizing enzymes (DMEs) UDP-glucuronosyltransferase (UGT). 100uM of isoliquiritigenin inhibited the activity of UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT1A10 by 95.2%, 76.1%, 78.9%, 87.2%, 67.2%, 94.8%, and 91.7%. Low concentration of ISL may have therapeutic potential in the treatment of aggressive breast carcinoma and other neoplasms. | |||||
In vivo | The tumorigenicity of ISL-treated cells was limited significantly in an animal model assay in vivo respectively. | |||||
Clinical Trials | N/A | |||||
Features | N/A |
相关产品
重组人肌球蛋白轻链2(Recombinant Human MYL2)
重组大鼠抵抗素(Rat Resistin)
大鼠酸性磷酸酶(ACP)ELISA Kit
大鼠胆囊收缩素/缩胆囊素八肽(CCK-8)ELISA Kit
人瘦素(LEP)ELISA Kit
重组人半乳糖凝集素16/LGALS16 Human
重组人半乳糖凝集素8/Human LGALS8 His
重组人半乳糖凝集素3/Human LGALS3 His
重组人卵泡抑素/Human FST His
重组人β防御素118/DEFB118 Human
重组人心肌营养素1/CTF1 Human
特级新生牛血清(无支原体)
超级新生牛血清(无支原体)
优级胎牛血清(无支原体)
特级新生牛血清(无噬菌体低内毒素)
详细地址
关注
拨打电话
留言咨询